Current news and events

Oslo University Hospital has awarded 6 excellent articles for the second half-year of 2018

Award winners during the ceremony

In order to stimulate excellent research and draw attention to the hospital's research activity, Oslo University Hospital reward outstanding publications every half-year.

Six research groups were awarded for their excellent papers published during the second half-year of 2018 on June 7th in the large auditorium at Ullevål sykehus. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.

Clinical studies - projects with many supporters

Krisina Schee (left) and Elin Westerheim

Clinical studies require a large amount of support. Many different professions work together towards a common goal, to deliver a study of good quality with reliable results.

Each year on the 20thof May, clinical studies are celebrated in honor of James Lind who conducted the first controlled study on sailors and scurvy. Krisina Schee (left) and Elin Westerheim from the Clinical Trial Unit at Oslo University Hospital the has written a blog where they illuminate the support staff and the different roles involved in a clinical study.

Johanna Olweus elected member of the executive board of CIMT

The past president, Christoph Huber, and the new president, Özlem Tureci, together with newly elected member of the Executive Board, Johanna Olweus

Johanna Olweus, Head of Dept of Cancer Immunology at the Institute for Cancer Research, OUS Radiumhospitalet, and Professor at the University of Oslo, was May 21 elected member of the executive board of CIMT during the CIMT 2019 conference for 900 participants in Mainz, Germany.
CIMT is the largest and most influential organization for Cancer Immunotherapy in Europe, and has had major global impact in the field. The board contains of a handful of world-renowned immunologists. 

Tor Erik Rusten's research presented:Autophagy - Hope or Threat to Cancer Patients?

Tor Erik Rusten (photo: Berit Langaard, OUS)

Tor Erik Rusten is heading the Tumor-Host Biology research group at the Department of Molecular Cell Biology at the Institute for Cancer Research. His research on autophagy has recently (May 23rd) been presented in a feature article in popular science form, published on the Oslo University Hospital home page (in Norwegian), entitled "Autophagy - Hope or Threat to Cancer Patients?".

New research blog:Clinical Trials – more than new drugs

Ellen Johnsen (left) and Martha Colban

Clinical trials play an important part in the development of new drugs. These trials are usually performed on a selected patient population in order to focus on the drug’s effect on the target indication. Hospital researchers may, however, see the need for clinical trials on a more diverse population, e.g. patients with additional diagnoses, or within areas that are not relevant for, or prioritised by, the pharmaceutical industry. The purpose might be to reduce drug consumption, finding new indications for existing drugs or identifying the most cost-effective treatments. Consequently, hospital researchers, trial staff and the patients participating in clinical trials all contribute to improved patient treatment and ensuring that health resources are spent wisely.

In connection with the "Clinical Trials Day" 2019 Ellen Johnsen and Martha Colban, Research Support  at Oslo University Hospital, have written a blog (in Norwegian) entitled " Clinical Trials – more than new drugs".

Clinical Trials Day - May 20th 2019Clinical studies - the road to better treatment

Jon B. Borgaard
The International Clinical Trials Day (ICTD) provides an opportunity to increase the awareness of clinical trials among the general public. We want to emphasize that clinical trials are essential for developing better treatments. We need more patients who take part in clinical trials, and we'd like to see that the number of clinical trials increase. The ICTD in many countries alsoprovides a well-deserved ‘time out’ to recognize the people who conduct clinical trials and to say “thanks” for what they do every day to improve public health. This day of celebration provides these communities with a unique opportunity to raise awareness of clinical trials – and of clinical research as a career option – among the greater public.
In connection with the "Clinical Trial Day" 2019 Jon B. Borgaard, head of the CTU department at Oslo University Hospital, has written a blog (in Norwegian) entitled "Clinical studies - the road to better treatment".

New genes linked to bipolar disorder

Ole Andreassen

A recent international large-scale study that included NORMENT has identified new genes in the human DNA that increase the risk of developing bipolar disorder.

The results were recently published in the prestigious journal Nature Genetics. Professor Ole A. Andreassen from the Division of Mental Health and Addiction at OUH and NORMENT was among the leaders of the study, and 13 NORMENT researchers and Norwegian collaborators also contributed.

Radforsk to invest NOK 4.5 million in cancer research

Anette Weyergang

Radforsk is an evergreen investor focusing on companies that develop cancer treatment. Since its start-up in 1986, Radforsk has ploughed NOK 200 million of its profit back into cancer research at Oslo University Hospital. This year, four researchers will be awarded a total of NOK 4.5 million. One of them is Anette Weyergang, who will receive NOK 3.75 million over a three-year period.

The first Norwegian CAR

Made in Oslo by a team of researchers from Oslo University Hospital, the first ever Norwegian CAR T cell is now a fact. A potential treatment based on this result depends on a clinical study.
The CAR (Chimeric Antigen Receptor) construct was designed, manufactured and validated in two laboratories in the Radium Hospital campus. One is headed by Else Marit Inderberg and Sébastien Wälchli and the other is led by June Helen Myklebust and Erlend B. Smeland.

More news from the archive